Axiom Real-Time Metrics Receives Investment from Great Point Partners
TORONTO, May 08, 2019 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services, today announces significant strategic growth funding. The investment has been led by Great Point Partners (“GPP”), a leading health care investment firm with approximately $1.6 billion of equity capital currently under management.
This event marks a significant milestone for Axiom, which was founded in 2001. Axiom, an established player in the eClinical market, is unique in its position in this space, as its significant growth has been accomplished through reinvestment of revenue, rather than through external investment. A strategic and pivotal decision for the organization, the collaboration with GPP represents the first investment of outside capital that Axiom has taken on.
The investment by GPP will position Axiom to accelerate the development and addition of leading-edge elements to its Fusion eClinical platform. Additionally, funds will be utilized to significantly expand professional services and business development initiatives.
“Our decision to work with Great Point Partners is based on our synergies, their hyper-focused area of life sciences, and the deep understanding of the space that they bring to the table. We are thrilled to be bringing onboard our first investment into Axiom with a group of their caliber”, shared Andrew Schachter, Founder and CEO.
Axiom is currently the leading provider of eClinical software and associated services to small to medium sized life sciences companies. It’s eClinical suite, Fusion, is enterprise level in its depth and scope, with all of its technology developed in-house. A key message of Axiom “We think differently”, is delivered upon through powerful, flexible and tailored solutions , priced to suit the needs of this small to medium-sized market, and providing service and a level of dedication in its client partnerships that is unmatched.
Andrew Schachter, Founder and CEO, continued, “I am very excited about GPP’s investment into Axiom that we are announcing today. Axiom has experienced tremendous continued growth over the past several years. My team and I have grown the company for over 18 years without taking external capital to date. We have built the Fusion eClinical Suite into the world class leading enterprise platform for EDC, IWRS, ePRO and CTMS operations focused on small to medium life sciences. As we continue to expand, this investment will augment innovation and resources for the breadth and depth of the Fusion platform, its modules and the accompanying services we wrap around them. We have a lot of exciting technologies and features to be released over the next few quarters to share with our clients.”
About Axiom Real-Time Metrics
Headquartered in Toronto, Canada, Axiom delivers intuitive, powerful and cost-effective eClinical solutions and services focused around your entire study. Services include: Data Management, Data Analytics, Biostatistics and Pharmacovigilance. Axiom's eClinical suite, Fusion, delivers a powerful range of innovative end-user focused, unified functionality and 15 modules. Axiom serves as the Connected Hub for your entire clinical study data and operational needs. Fusion Delivers: EDC, DM, IWRS, CTMS, Inventory Management, IVR, Patient Portal, AE/SAE Tracking, Safety Database, Central Lab, Imaging, eTMF, and 24/7 Project and Clinical Data Reporting. For more information, please visit http://www.axiommetrics.com/.
Contact
solutions@axiom.cc +1.877.321.9191
PR Contact
Sarah Glofcheskie
sarahg@axiom.cc +1.647.588.9073
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.5 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has over $280 million in committed capital) and public (BioMedical Value Fund, approximately $1.1 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
EVS Broadcast Equipment reports third quarter 2019 Trading update14.11.2019 06:30:00 CET | Press release
Publication on November 14, 2019, before market opening Regulated information – Press release Business Updates EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS Q3 2019 Business update >EVS global leader in live video technology for broadcast and new media productions today announces its business update for the third quarter ending 30 September 2019. HIGHLIGHTS Appointment of Serge Van Herck as new CEO The Broadcast Market conditions remain difficult with slower than anticipated transition to UHD (4K) In APAC region, political and trade relation issues are creating uncertainty and delayed investment decisions that negatively impact EVS Business Slower order intake due to market conditions, full year revenues are expected between EUR 100 million – EUR 110 million Improvement of the guidance on OPEX from flat opex to moderate decline around -3% Year over Year thanks to strict cost management and cost reductions initiatives Distribution of
Equinor ASA: Transaksjoner i kapitalmarkedet13.11.2019 22:31:00 CET | Pressemelding
Onsdag 13. november 2019 gjennomførte Equinor ASA (OSE:EQNR, NYSE:EQNR), med garanti fra Equnior Energy AS, følgende transaksjon i kapitalmarkedet: - Utstedelse av obligasjonslån pålydende USD 1.000.000.000 med 3,25% i kupong, forfall 18. november 2049 Lånebeløpet skal benyttes til finansiering av selskapets aktiviteter generelt. Dette kan inkludere tilbakebetaling og tilbakekjøp av utestående gjeld eller andre formål beskrevet i tilleggsprospektet utarbeidet for denne låneutstedelsen. Transaksjonen vil styrke Equinors finansielle fleksibilitet. Lånet er fulltegnet. Oppgjørsdato er 18. november 2019. Enhver offentlig utstedelse i USA er gjort utelukkende med grunnlag i et tilleggsprospekt til prospektet inkludert i Equinor ASA og Equinor Energy AS' gjeldende registreringsdokument hos Securities and Exchange Commission i USA. Kontaktpersoner: Investorrelasjoner: Peter Hutton, Senior Vice President, Investor Relations, +44 788 191 8792 Helge Hove Haldorsen, Vice President, Investor Relat
Equinor ASA: Execution of debt capital market transactions13.11.2019 22:31:00 CET | Press release
On Wednesday November 13, 2019 Equinor ASA (OSE:EQNR, NYSE:EQNR), guaranteed by Equinor Energy AS, executed the following debt capital market transaction: - Issue of USD 1,000,000,000 3.25% Notes due November 18, 2049 The net proceeds from the issue of the Notes will be used for general corporate purposes, which may include the repayment or purchase of existing debt or other purposes described in the prospectus supplement for the issue of Notes. The transaction will increase the financial flexibility of the company. The Notes have been fully subscribed. The settlement date is November 18, 2019. Any public offering in the United States is being made solely by means of a prospectus supplement to the prospectus included in the Registration Statement filed by Equinor ASA and Equinor Energy AS, and previously declared effective. Further information from: Investor relations: Peter Hutton, Senior Vice President, Investor Relations, +44 788 191 8792 Helge Hove Haldorsen, Vice President, Invest
Transparency notification – Gilead holds 25.10% of Galapagos shares13.11.2019 22:01:00 CET | Press release
Mechelen, Belgium; 13 November 2019; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 11 November 2019 from Gilead Sciences, Inc. (acting as a parent undertaking or a controlling person), who notified that Gilead Therapeutics A1 Unlimited Company, an indirect subsidiary of Gilead Sciences, Inc., holds 16,207,477 of Galapagos' voting rights, consisting of 16,207,477 shares, as a result of subscribing to a capital increase in the framework of the exercise of the Initial Warrant A and thus receiving 2,617,791 new Galapagos shares on 6 November 2019. This represents 25.10% of Galapagos' currently outstanding 64,571,622 shares. Gilead Therapeutics A1 Unlimited Company thus crossed above the 25% threshold of Galapagos' voting rights by acquisition of voting securities on 6 November 2019. The notification spec
Yara annonserer stenging av fabrikk i Trinidad13.11.2019 19:00:00 CET | Pressemelding
Oslo, 13. november 2019: Yara annonserer stenging av sin heleide fabrikk i Point Lisas, Trinidad. Fabrikken er ett av tre ammoniakkanlegg drevet av Yara Trinidad Ltd. De to gjenværende anleggene, Tringen I og Tringen II, er eid av Yara sammen med National Enterprises Ltd (NEL). Fabrikken i Trinidad er en av Yara sine minste ammoniakkanlegg, med en årlig produksjonskapasitet på omtrent 270.000 tonn ammoniakk. I tillegg til begrenset skala har fabrikken lavere energieffektivitet enn gjennomsnittet av Yaras fabrikker. Fabrikkens lønnsomhet har dessuten vært påvirket av fallende ammoniakkpriser, og i tillegg har forhandlingene med The National Gas Company of Trinidad and Tobago (NGC) ikke lykkes i å oppnå en avtale som kunne sikret videre drift av fabrikken. Yara vil iverksette tiltak for å stenge fabrikken og avslutte produksjonen innen 31. desember 2019. Stengingen er tentativt forventet å generere en kostnad på omtrent USD 25 millioner som vil bli klassifisert som en spesiell post i Yar
Volta Finance Limited Net Asset Value as at 31 October 201913.11.2019 19:00:00 CET | Press release
Volta Finance Limited (VTA / VTAS) – October 2019 monthly report NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ***** Guernsey, 13 November 2019 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for October. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY In October, Volta’s NAV* total return performance was -2.6%. The YTD performance is 3.1%. This relatively modest performance YTD is mostly due to the widening of discount margins in the CLO market although there has been a significant difference in the recent performances of CLO debt and CLO Equity. Indeed, the monthly performances ** of the sub-asset classes were the following, in local currency: +0.7% for Bank Balance Sheet transactions, -1.0% for CLO Equity tranches; -3.5% for CLO Debt; -4.9% for Cash Corporate Credit deals;